1 / 11

The Medicines Transparency Alliance

The Medicines Transparency Alliance. Saul Walker Senior Policy Advisor, Access to Medicines Health Services Team. Pharmaceutical markets. Public and private International and local interactions Information asymmetry Manufacturer/(regulator)/purchaser Wholesaler/Retailer

kennan
Download Presentation

The Medicines Transparency Alliance

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Medicines Transparency Alliance Saul Walker Senior Policy Advisor, Access to Medicines Health Services Team

  2. Pharmaceutical markets • Public and private • International and local interactions • Information asymmetry • Manufacturer/(regulator)/purchaser • Wholesaler/Retailer • Prescriber/(Dispenser)/Patient • Lack of information • Irrational – unaligned incentives

  3. Efficiency (public/private) Mutual Accountability Transparency Better policies, improved business practice & stronger implementation Validated Information & Appropriate Disclosure The hypothesis … Multi-stakeholder disclosure & scrutiny

  4. Medicines Transparency Alliance 7 countries committed to work across government, private sector and civil society to disclose data on medicines price, quality, availability and promotion

  5. Country Priorities • Commit to disclosure and multi-stakeholder approach • Must include CSOs and private sector • Decide where to locate secretariat and stakeholder group • Agree priority areas and work plan • Guidance on disclosure from International Secretariat • Methodologies and technical support

  6. New validated Changes in drug data on prices, pharmaceutical availability, sector quality and/or promotion Policy research, shared learning Sector plans, domestic and CPs ££, toolkit & technical support The Pilot Pilot Disclosure of Disclosure of New validated New validated Changes in drug Changes in drug data and data and data on data on Policy change Policy change prices, prices, scrutiny by scrutiny by Development of Development of pharmaceutical pharmaceutical and and availability, availability, multi multi - - policy options policy options sector sector implementation implementation quality and/or quality and/or stakeholder stakeholder promotion promotion group group . . Improved information for Improved information for Improved processes Improved processes management management

  7. Priorities chosen by countries

  8. Data disclosure (in addition to baseline) • Pricing (Peru and Uganda) • Availability and promotion (Jordan and Zambia); • Transparency and accountability (Philippines - GGM) • Quality (Kyrgyzstan and Ghana); • Health insurance data mining (Ghana) • RUM (Uganda and Jordan)

  9. Progress and Next Steps • All countries have agreed work plans – took longer than we expected • Implementation now underway – focus on newly disclosing & using information • Baseline surveys underway • Sector scan, availability, multi-stakeholder working – significant new data resources • Process evaluation 1Q10 – inform decisions and design for post-pilot

  10. Questions • Disclosure – what, when and to whom? • Multi-stakeholder approach or multi-stakeholder analysis? • Catalysing support from others? • Adding value or adding confusion?

  11. www.medicinestransparency.org

More Related